BEIJING LEADMAN BIOCHEMISTRY CO.,LTD. Financials Beijing Leadman Biochemistry Co.,Ltd.
Equities
300289
CNE100001C22
Medical Equipment, Supplies & Distribution
|
End-of-day quote
Other stock markets
|
5-day change | 1st Jan Change | ||
| 4.31 CNY | -3.36% |
|
+4.87% | -29.92% |
Valuation
| Fiscal Period: December | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 |
|---|---|---|---|---|---|---|
| Capitalization 1 | 2,775 | 2,432 | 2,461 | 4,390 | 3,134 | 3,346 |
| Enterprise Value (EV) 1 | 2,622 | 2,184 | 2,157 | 3,475 | 2,347 | 2,499 |
| P/E ratio | 73.2 x | 371 x | -49.1 x | 161 x | -57.6 x | 205 x |
| Yield | - | 0.17% | - | 0.25% | - | 0.16% |
| Capitalization / Revenue | 4.24 x | 4.72 x | 5.22 x | 7.78 x | 4.44 x | 7.25 x |
| EV / Revenue | 4 x | 4.24 x | 4.57 x | 6.16 x | 3.32 x | 5.41 x |
| EV / EBITDA | 22.6 x | 26.1 x | 72.2 x | 28.5 x | 30.7 x | 32 x |
| EV / FCF | 23.9 x | 15.6 x | 17.7 x | 36.6 x | 45.7 x | 31.9 x |
| FCF Yield | 4.18% | 6.43% | 5.66% | 2.73% | 2.19% | 3.14% |
| Price to Book | 2.1 x | 1.85 x | 1.95 x | 2.39 x | 1.81 x | 1.92 x |
| Nbr of stocks (in thousands) | 421,052 | 417,798 | 417,798 | 544,011 | 544,011 | 544,011 |
| Reference price 2 | 6.590 | 5.820 | 5.890 | 8.070 | 5.760 | 6.150 |
| Announcement Date | 4/22/19 | 4/2/20 | 4/23/21 | 3/18/22 | 3/25/23 | 3/27/24 |
1CNY in Million2CNY
Estimates
Income Statement Evolution (Annual data)
| Fiscal Period: December | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 |
|---|---|---|---|---|---|---|
| Net sales 1 | 654.8 | 515.1 | 471.5 | 564.1 | 706 | 461.6 |
| EBITDA 1 | 116.3 | 83.68 | 29.89 | 121.9 | 76.55 | 78.15 |
| EBIT 1 | 75.85 | 39.7 | -22.12 | 66.62 | 17.94 | 20.02 |
| Operating Margin | 11.58% | 7.71% | -4.69% | 11.81% | 2.54% | 4.34% |
| Earnings before Tax (EBT) 1 | 72.61 | 31.52 | -14.79 | 58.8 | -25.16 | 24.53 |
| Net income 1 | 40.47 | 6.309 | -50.98 | 22.42 | -56.27 | 15.34 |
| Net margin | 6.18% | 1.22% | -10.81% | 3.97% | -7.97% | 3.32% |
| EPS 2 | 0.0900 | 0.0157 | -0.1200 | 0.0500 | -0.1000 | 0.0300 |
| Free Cash Flow 1 | 109.6 | 140.4 | 122 | 94.9 | 51.4 | 78.37 |
| FCF margin | 16.74% | 27.26% | 25.88% | 16.82% | 7.28% | 16.98% |
| FCF Conversion (EBITDA) | 94.29% | 167.81% | 408.32% | 77.83% | 67.14% | 100.28% |
| FCF Conversion (Net income) | 270.88% | 2,225.76% | - | 423.28% | - | 510.99% |
| Dividend per Share | - | 0.0100 | - | 0.0200 | - | 0.0100 |
| Announcement Date | 4/22/19 | 4/2/20 | 4/23/21 | 3/18/22 | 3/25/23 | 3/27/24 |
1CNY in Million2CNY
Estimates
Balance Sheet Analysis
| Fiscal Period: December | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 |
|---|---|---|---|---|---|---|
| Net Debt 1 | - | - | - | - | - | - |
| Net Cash position 1 | 153 | 247 | 304 | 915 | 787 | 846 |
| Leverage (Debt/EBITDA) | - | - | - | - | - | - |
| Free Cash Flow 1 | 110 | 140 | 122 | 94.9 | 51.4 | 78.4 |
| ROE (net income / shareholders' equity) | 4.34% | 1.94% | -2.08% | 2.81% | -1.92% | 1.26% |
| ROA (Net income/ Total Assets) | 2.72% | 1.44% | -0.83% | 2.09% | 0.52% | 0.64% |
| Assets 1 | 1,487 | 437.8 | 6,165 | 1,071 | -10,907 | 2,414 |
| Book Value Per Share 2 | 3.140 | 3.150 | 3.020 | 3.370 | 3.180 | 3.200 |
| Cash Flow per Share 2 | 0.6500 | 0.7100 | 0.8400 | 1.710 | 1.470 | 1.040 |
| Capex 1 | 12.2 | 26.3 | 28.4 | 44.5 | 39.1 | 18.7 |
| Capex / Sales | 1.87% | 5.1% | 6.02% | 7.89% | 5.54% | 4.05% |
| Announcement Date | 4/22/19 | 4/2/20 | 4/23/21 | 3/18/22 | 3/25/23 | 3/27/24 |
1CNY in Million2CNY
Estimates
EPS & Dividend
Year-on-year evolution of the PER
Change in Enterprise Value/EBITDA
Annual profits - Rate of surprise
| 1st Jan change | Capi. | |
|---|---|---|
| -29.92% | 324M | |
| +0.89% | 12.8B | |
| -10.29% | 7.61B | |
| -1.16% | 4.51B | |
| +5.74% | 4.49B | |
| -50.70% | 3.3B | |
| +12.21% | 2.73B | |
| -16.13% | 2.02B | |
| -11.50% | 1.73B | |
| -5.02% | 1.64B |
- Stock Market
- Equities
- 300289 Stock
- Financials Beijing Leadman Biochemistry Co.,Ltd.
